News & Analysis as of

Amgen Patent-in-Suit

Robins Kaplan LLP

Amgen Inc. v. Sandoz Inc. Otezla® (Apremilast)

Robins Kaplan LLP on

Case Name: Amgen Inc. v. Sandoz Inc., Nos. 2022-1147, 2022-1149, 2022-1150, 2022-1151, 2023 WL 2994166 (Fed. Cir. Apr. 19, 2023) (Circuit Judges Lourie, Cunningham, and Stark presiding; Opinion by Lourie, J.) (Appeal from...more

McDonnell Boehnen Hulbert & Berghoff LLP

Amgen Files Reply Brief in Amgen v. Sanofi

Amgen recently filed its Reply brief to the Supreme Court in Amgen v. Sanofi.  While a conventional proportion of Amgen's Reply is directed to arguments Respondent Sanofi made in its brief, at trial, and before the Federal...more

Robins Kaplan LLP

Amgen Inc. v. Amneal Pharms. LLC

Robins Kaplan LLP on

Case Name: Amgen Inc. v. Amneal Pharms. LLC, 2018-2414, 2019-1086, 2020 U.S. App. LEXIS (Fed. Cir. Jan. 7, 2020) (Circuit Judges Newman, Lourie, and Taranto presiding; Opinion by Lourie, J.) (Appeal from D. Del., Goldberg,...more

Robins Kaplan LLP

Amgen Inc. v. Amneal Pharms. LLC

Robins Kaplan LLP on

THE COURT DENIED DEFENDANT’S MOTION TO ENFORCE ITS SETTLEMENT AGREEMENT WITH PLAINTIFF AFTER THE AT-RISK LAUNCH AND SUBSEQUENT SETTLEMENT OF ANOTHER DEFENDANT. Case Name: Amgen Inc. v. Amneal Pharms. LLC, No. 16-853-MSG...more

Robins Kaplan LLP

Amgen Inc. v. Amneal Pharms. LLC

Robins Kaplan LLP on

The Court Denied Defendant’s Motion To Enforce Its Settlement Agreement With Plaintiff After The At-risk Launch And Subsequent Settlement Of Another Defendant. ...more

Robins Kaplan LLP

Cipla Ltd. v. Amgen Inc.

Robins Kaplan LLP on

Case Name: Cipla Ltd. v. Amgen Inc., No. 19-44-LPS, 2019 U.S. Dist. LEXIS 74970 (D. Del. May 2, 2019) (Stark, J.) - Drug Product and Patent(s)-in-Suit: Sensipar® (cinacalcet HCl); U.S. Patent No. 9,375,405 (“the ’405...more

Dechert LLP

Federal Circuit Panel Describes the Doctrine of Equivalents as Applying “Only in Exceptional Cases”

Dechert LLP on

In a patent owner’s declaratory judgment action under the Biologics Price Competition and Innovation Act (“BPCIA”) a Federal Circuit panel in Amgen Inc. v. Sandoz Inc., Appeal No. 2018-1551 (Fed. Cir. May 8, 2019) narrowly...more

Robins Kaplan LLP

Amgen Inc. v. Amneal Pharms. LLC

Robins Kaplan LLP on

Case Name: Amgen Inc. v. Amneal Pharms. LLC, Civ. No. 16-0853 (MSG), 2018 U.S. Dist. LEXIS 125631 (D. Del. July 27, 2018) (Goldberg, J.)....more

Robins Kaplan LLP

Amgen Inc. v. Alkem Labs. Ltd.

Robins Kaplan LLP on

Case Name: Amgen Inc. v. Alkem Labs. Ltd., Civ. No. 17-cv-815-GMS, -817-GMS, 2017 U.S. Dist. LEXIS 208124 (D. Del. Dec. 19, 2017) (Sleet, J.). Drug Product and Patent(s)-in-Suit: Sensipar® (cinacalcet HCl); U.S. Patent...more

Goodwin

ABBVIE V. AMGEN: The Parties Request A Bench Trial In November 2019

Goodwin on

Today, in the AbbVie v. Amgen adalumimab case, the parties filed a joint proposed scheduling order. The parties jointly proposed a bench trial commencing the week of November 4, 2019, with completion of fact discovery by...more

10 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide